Dr Agarwals Healthcare IPO

Incorporated in 2010, Dr. Agarwal's Health Care Limited offers a comprehensive range of eye care services, including cataract and refractive surgeries, consultations, diagnoses, non-surgical treatments, and the sale of optical products, contact lenses, accessories, and eye care-related pharmaceutical items. As of September 30, 2024, there were 737 doctors providing care to patients across the company's facilities. During this period, the company served 2.13 million patients and performed 220,523 surgeries. In the six months leading up to September 30, 2024, they served 1.15 million patients and conducted 140,787 surgeries. The Services provided by the company are:- Cataract surgeries Offer cataract surgical treatments at its Facilities, such as small incision cataract surgery, phacoemulsification, robotic cataract surgery and glued intraocular lens treatments; Refractive surgeries: Refractive surgeries are procedures that correct eye refractive errors, helping individuals reduce or eliminate their need for glasses and contact lenses. The main types include LASIK, SMILE, implantable collamer lenses, and photorefractive keratectomy (PRK). Other surgeries: Offer a range of other surgical treatments for eye ailments, such as surgical retinal treatments, corneal transplantation and pinhole pupilloplasty, oculoplasty and surgeries for the treatment of glaucoma and pterygium. As of September 30, 2024, the company's Indian network has 28 hubs (Tertiary Facilities, including three COEs) and 165 spokes (53 Primary and 112 Secondary Facilities). As of September 30, 2024, the company has a presence in India across 117 metro and non-metro cities spanning 14 states and four union territories through 193 Facilities. Competitive Strength Largest eye care services provider in India with a trusted brand End-to-end, comprehensive eye care services offering Scalable, asset-light, hub-and-spoke operating model Proven clinical excellence is driven by a strong clinical board and a history of surgical innovations.  Doctor-promoters leading a team of qualified medical professionals and supported by experienced management Proven track record of delivering organic growth, integrating and scaling acquisitions and improving operating profitability

The Company proposes to utilise the Net Proceeds from the Fresh Issue towards funding of the following objects: Repayment/prepayment, in part or full, of certain of the borrowings and General corporate purposes and unidentified inorganic acquisition.

All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions. We are not a SEBI Registered analyst. Readers must consult a qualified financial advisor prior to making any actual investment decisions, based on Information published on this application. No financial information whatsoever published anywhere, within this application, should be considered as advice to buy or sell securities or invest in IPOs, or as a guide to doing so in any way whatsoever Please read all Tearms and conditions , and agree to use the App